Compare FGBI & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | BDSX |
|---|---|---|
| Founded | 1934 | 2005 |
| Country | United States | United States |
| Employees | 339 | N/A |
| Industry | Savings Institutions | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 122.0M |
| IPO Year | N/A | 2020 |
| Metric | FGBI | BDSX |
|---|---|---|
| Price | $8.32 | $14.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 5.6K | ★ 136.3K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | $567.70 | $25.26 |
| Revenue Next Year | N/A | $19.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $4.31 | $0.25 |
| 52 Week High | $10.55 | $20.21 |
| Indicator | FGBI | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 47.32 |
| Support Level | $7.79 | $6.33 |
| Resistance Level | $8.33 | $20.21 |
| Average True Range (ATR) | 0.28 | 1.69 |
| MACD | -0.06 | -0.56 |
| Stochastic Oscillator | 22.49 | 3.15 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.